No DFS Benefit With Adjuvant Durvalumab in Early NSCLC ...Middle East

The lack of a disease-free survival benefit with adjuvant durvalumab in early-stage resected non-small cell lung cancer in the CCTG BR.31 trial underscores the need to identify biomarkers. Medscape Medical News

Hence then, the article about no dfs benefit with adjuvant durvalumab in early nsclc was published today ( Saturday 14/09/2024 - 09:14 PM ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( No DFS Benefit With Adjuvant Durvalumab in Early NSCLC )

Also on site :

• The Dietitian-Approved Starbucks Matcha Order You Need To Try
• Bulgaria wins Eurovision as Israel finishes second amid protests
• Fresca Turns Its Popular Citrus Soda Into 4 Boozy New Drinks